Total Payments
$572.79
2024 Payments
$89.41
Companies
8
Transactions
17
Medicare Patients
40,326
Medicare Billing
$16.2M
Payment Breakdown by Category
Food & Beverage$333.31 (58.2%)
Education$208.23 (36.4%)
Other$31.25 (5.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $333.31 | 5 | 58.2% |
| Education | $208.23 | 9 | 36.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31.25 | 1 | 5.5% |
| Unspecified | $0 | 2 | 0.0% |
Payments by Type
General
$572.79
15 transactions
Ownership
$0
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Seagen Inc. | $100.92 | 2 | $0 (2022) |
| Incyte Corporation | $99.95 | 1 | $0 (2018) |
| Amgen Inc. | $98.33 | 1 | $0 (2017) |
| Seattle Genetics, Inc. | $93.81 | 5 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $89.41 | 1 | $0 (2024) |
| PFIZER INC. | $78.45 | 4 | $0 (2023) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $89.41 | 1 | E.R. Squibb & Sons, L.L.C. ($89.41) |
| 2023 | $25.00 | 1 | PFIZER INC. ($25.00) |
| 2022 | $15.57 | 1 | Seagen Inc. ($15.57) |
| 2021 | $97.27 | 2 | Seagen Inc. ($85.35) |
| 2019 | $24.58 | 2 | Seattle Genetics, Inc. ($24.58) |
| 2018 | $155.78 | 5 | Incyte Corporation ($99.95) |
| 2017 | $165.18 | 5 | Amgen Inc. ($98.33) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/22/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $89.41 | General |
| Category: Oncology | ||||||
| 08/09/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 05/13/2022 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/06/2021 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $85.35 | General |
| Category: Oncology | ||||||
| 03/20/2019 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 02/15/2019 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 08/28/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 06/30/2018 | PFIZER INC. | BOSULIF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $31.25 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 04/24/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 03/16/2018 | Incyte Corporation | — | Education | Cash or cash equivalent | $99.95 | General |
| 2018 | MRI Interventions, Inc. | — | — | — | $0.00 | Ownership |
| 12/19/2017 | PFIZER INC. | SUTENT (Drug) | Education | In-kind items and services | $11.40 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 07/08/2017 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $44.65 | General |
| Category: Not Applicable | ||||||
| 06/28/2017 | PFIZER INC. | BAVENCIO (Drug) | Education | In-kind items and services | $10.80 | General |
| Category: ONCOLOGY | ||||||
| 06/26/2017 | Amgen Inc. | Kyprolis (Biological) | Food and Beverage | In-kind items and services | $98.33 | General |
| Category: Oncology | ||||||
| 2017 | MRI Interventions, Inc. | — | — | — | $0.00 | Ownership |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 86 | 8,801 | 292,485 | $18.4M | $3.5M |
| 2022 | 103 | 9,990 | 290,036 | $20.4M | $4.0M |
| 2021 | 122 | 10,915 | 345,490 | $19.8M | $4.1M |
| 2020 | 117 | 10,620 | 345,224 | $20.9M | $4.5M |
Total Patients
40,326
Total Services
1,273,235
Medicare Billing
$16.2M
Procedure Codes
428
All Medicare Procedures & Services
428 procedure records from CMS Medicare Utilization — Page 1 of 18
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 31 | 27,800 | $4.1M | $1.2M | 29.5% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 16 | 31,340 | $2.6M | $742,879 | 29.0% |
| J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg | Office | 2023 | 11 | 18,600 | $1.3M | $380,769 | 29.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 58 | 9,480 | $664,860 | $172,206 | 25.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 904 | 2,026 | $365,794 | $128,178 | 35.0% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 36 | 53,540 | $1.1M | $126,440 | 11.2% |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2023 | 11 | 11,500 | $494,500 | $116,513 | 23.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 157 | 825 | $688,438 | $81,175 | 11.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 331 | 737 | $222,456 | $68,746 | 30.9% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 20 | 576 | $831,744 | $46,673 | 5.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 917 | 4,010 | $248,620 | $41,345 | 16.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 946 | 4,531 | $158,585 | $34,321 | 21.6% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 14 | 336 | $295,344 | $29,812 | 10.1% |
| J9394 | Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg | Office | 2023 | 15 | 2,280 | $305,520 | $28,310 | 9.3% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 35 | 20,540 | $184,860 | $27,893 | 15.1% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 15 | 6,465 | $801,660 | $25,785 | 3.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 781 | 2,735 | $51,965 | $22,920 | 44.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 38 | 320 | $79,731 | $17,515 | 22.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 119 | 1,452 | $152,460 | $16,979 | 11.1% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 412 | 820 | $101,680 | $16,539 | 16.3% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 22 | 91 | $89,726 | $16,055 | 17.9% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 43 | 198 | $13,860 | $13,583 | 98.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 63 | 265 | $107,887 | $13,020 | 12.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 78 | 78 | $45,242 | $12,305 | 27.2% |
| 83520 | Measurement of substance using immunoassay technique | Office | 2023 | 73 | 628 | $113,668 | $10,629 | 9.4% |
About Dr. Thomas Alberico, MD
Dr. Thomas Alberico, MD is a Hematology & Oncology healthcare provider based in Norfolk, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1922001064.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Alberico, MD has received a total of $572.79 in payments from pharmaceutical and medical device companies, with $89.41 received in 2024. These payments were reported across 17 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($333.31).
As a Medicare-enrolled provider, Alberico has provided services to 40,326 Medicare beneficiaries, totaling 1,273,235 services with total Medicare billing of $16.2M. Data is available for 4 years (2020–2023), covering 428 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Norfolk, VA
- Active Since 05/23/2005
- Last Updated 01/17/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1922001064
Products in Payments
- TUKYSA (Drug) $100.92
- Kyprolis (Biological) $98.33
- ADCETRIS (Biological) $93.81
- OPDIVO (Biological) $89.41
- BOSULIF (Drug) $31.25
- IBRANCE (Drug) $25.00
- SUTENT (Drug) $11.40
- BAVENCIO (Drug) $10.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Norfolk
Rabih Fahed, M.d, M.D
Hematology & Oncology — Payments: $337,010
Hematology & Oncology $337,010
Gary Simmons, Do, DO
Hematology & Oncology — Payments: $66,315
Hematology & Oncology $66,315
Michael Danso, M.d, M.D
Hematology & Oncology — Payments: $54,407
Hematology & Oncology $54,407
Dr. Shanley Banaag, D.o, D.O
Hematology & Oncology — Payments: $3,419
Hematology & Oncology $3,419
Dr. Ranjit Goudar, M.d, M.D
Hematology & Oncology — Payments: $549.21
Hematology & Oncology $549.21
Boon Cheng Kok, Md, MD
Hematology & Oncology — Payments: $539.63
Hematology & Oncology $539.63